Abstract
BackgroundNNC0109-0012 is a novel human monoclonal IgG4 antibody which binds to and neutralises the activity of IL-20. Phase 1 single-dose results did not raise any safety concerns for NNC0109-0012 in...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have